Johnson & Johnson (NYSE:JNJ) Receives $202.10 Average Price Target from Brokerages

Shares of Johnson & Johnson (NYSE:JNJ) have been given a consensus rating of “Moderate Buy” by the twenty-six brokerages that are presently covering the stock, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $203.15.

JNJ has been the topic of a number of research reports. Royal Bank Of Canada restated an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a report on Friday, October 10th. Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, Stifel Nicolaus boosted their price target on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th.

Johnson & Johnson Stock Down 0.3%

JNJ stock opened at $201.92 on Wednesday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $207.81. The company has a market capitalization of $486.48 billion, a price-to-earnings ratio of 19.49, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. The business’s 50 day moving average price is $194.05 and its two-hundred day moving average price is $175.56. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds have recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Smart Money Group LLC boosted its position in shares of Johnson & Johnson by 6.5% during the first quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock valued at $1,109,000 after buying an additional 407 shares during the last quarter. United Bank boosted its position in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after buying an additional 4,876 shares during the last quarter. Advyzon Investment Management LLC increased its holdings in Johnson & Johnson by 8.9% in the 1st quarter. Advyzon Investment Management LLC now owns 5,514 shares of the company’s stock worth $914,000 after buying an additional 452 shares in the last quarter. Finally, Cary Street Partners Financial LLC lifted its stake in Johnson & Johnson by 15.6% during the 1st quarter. Cary Street Partners Financial LLC now owns 129,965 shares of the company’s stock valued at $21,553,000 after acquiring an additional 17,510 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.